Irish Journal of Medical Science

, Volume 169, Issue 4, pp 241–244 | Cite as

Cost of treating heart failure in an Irish teaching hospital

  • B. McGowan
  • A. Heerey
  • M. Ryan
  • M. Barry
Original Paper



The prevalence of heart failure is 3 to 20 per 1,000 population, but may exceed 100 per 1,000 in the over 65 age group. Some 1–2% of the total healthcare budget is consumed in the management of heart failure.


As hospital costs account for approximately 70% of this expenditure we determined the cost of treating heart failure in an Irish teaching hospital.


Cost evaluation was from the hospital perspective using a microcosting detailed collection of resources used.


The average cost of a hospital admission for cardiac failure was IR£2,146. The average cost per day was IR£193. Approximately 75% of hospital costs were associated with ward costs. Medications accounted for 3.5% of total costs.


The availability of Irish cost data is essential for the assessment of the cost-effectiveness of therapeutic interventions for the treatment of heart failure in our healthcare system.


Heart Failure Digoxin Chronic Heart Failure Cardiac Failure Irish Journal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Watson RDS, Gibbs CR, Lip GYH. ABC of heart failure: clinical features and complications.BMJ 2000; 320: 236–9CrossRefPubMedGoogle Scholar
  2. 2.
    McMurray JJV, Petrie MC, Murdoch DR, Davie AR. Clinical epidemiology of heart failure: public and private health burden.Eur Heart J 1998; 19 (Suppl P): 9–16Google Scholar
  3. 3.
    Parameshwar J, Poole-Wilson PA, Sutton GC. Heart failure in a district general hospital.JR Coll Physicians Lond 1992; 26: 139–42Google Scholar
  4. 4.
    McMurray J, McDonagh T, Morrison CE et al. Trends in hospitalisation for chronic heart failure in Scodand.Eur Heart J 1993; 14: 1158–62PubMedGoogle Scholar
  5. 5.
    McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure.Pharmacoeconomics 1996; 9 (3): 188–97CrossRefPubMedGoogle Scholar
  6. 6.
    Bonneux L, Barendregt JJ, Meeter K et al. Estimating clinical morbidity due to ischaemic heart disease and congestive heart failure: the future rise of heart failure.Am J Public Health 1994; 84: 20–8CrossRefPubMedGoogle Scholar
  7. 7.
    Brophy JM, Deslauriers G, Boucher B et al. The hospital course and short-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure.Can J Cardiol 1993; 9 (3): 219–24PubMedGoogle Scholar
  8. 8.
    Weingarten SR, Reidinger MS, Shinbane J et al. Triage practice guideline for patients hospitalised with congestive heart failure: improving the effectiveness of the coronary care unit.Am J Med 1993; 94: 483–90CrossRefPubMedGoogle Scholar
  9. 9.
    Lip YH, Gibbs CR, Beevers DG. ABC of heart failure: aetiology.BMJ 2000; 320: 104–6CrossRefPubMedGoogle Scholar
  10. 10.
    Cheeseman MG, Leech G, Chambers J et al. Central role of echocardiography in the diagnosis and assessment of heart failure.Heart 1998; 80 (Suppl): 1–5Google Scholar
  11. 11.
    Loeb HS, Johnson G, Henrick A et al. Effect of enalapril, hydralazine plus isosorbide dinitrate and prazosin on hospitalisation in patients with chronic congestive cardiac failure.Circulation 1993; 87 (Suppl VI): 178–87Google Scholar
  12. 12.
    Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991; 325: 293–302Google Scholar
  13. 13.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure.N Engl J Med 1987; 316: 1429–35Google Scholar
  14. 14.
    McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK.Br J Med Econ 1993; 6: 91–8Google Scholar
  15. 15.
    Packer M, Poole-Wilson P, Armstrong P et al. Comparative effects of low dose versus high dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival study (ATLAS).Eur Heart J 1998; (Abstract) 142Google Scholar
  16. 16.
    van Veldhuisen DJ, Charlesworth A, Crijns H, Lie K, Hampton JR. Differences in drug treatment of chronic heart failure between European countries.Eur Heart J 1999; 20: 666–72CrossRefPubMedGoogle Scholar
  17. 17.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors.N Engl J Med 1993; 329: 1–7CrossRefPubMedGoogle Scholar
  18. 18.
    Uretsky BF, Young JB, Shahid FE et al. Randomised study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial.J Am Coll Cardiol 1993; 22: 955–62PubMedCrossRefGoogle Scholar
  19. 19.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure.N Engl J Med 1997; 336: 525–33CrossRefGoogle Scholar
  20. 20.
    Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure.Eur Heart J 1998; 19 (Suppl P): 32–9Google Scholar
  21. 21.
    CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial.Lancet 1999; 353: 9–13CrossRefGoogle Scholar
  22. 22.
    Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med 1999; 341: 709–17CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2000

Authors and Affiliations

  1. 1.National Centre for PharmacoeconomicsSt James’s HospitalDublin 8

Personalised recommendations